Compare Incyte Corporation (INCY) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Twilio Inc — how do they compare? Incyte Corporation trades at $120.76 (market cap $24.54B), while Twilio Inc trades at $244.6 (market cap $39.31B). The key difference: Twilio Inc is the larger of the two by market cap, and Twilio Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | TWLO | |
|---|---|---|
Market Cap | $24.54B | $39.31B |
Sector | Health | Technology |
52-Week High | $129.93 | $255.95 |
52-Week Low | $81.61 | $95.23 |
Enterprise Value | $20.04B | $37.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Twilio (TWLO) trades at $247.10, down 1.18% on the day, but remains near its 52-week high after a strong rally driven by Q2 2026 earnings beats and raised guidance. The stock shows bullish technical signals with support at $246 and resistance at $259. Revenue growth accelerated to 22% year-over-year in Q2, with net income turning positive in 2025 after years of losses, reflecting improved profitability and cash flow generation.
Outlook is positive with Wall Street consensus Buy rating and $266.31 price target, though high valuation multiples (P/E 35.35) and overbought RSI levels suggest near-term consolidation risk. Key opportunities include AI-driven growth and expanding free cash flow margins, while risks involve competitive pressures and execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
